Abstract
The purpose of this study was to assess the impact of pentoxifylline and vitamin E on the incidence and severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients. This is a prospective, randomized, controlled study. Head and neck cancer patients receiving 30–35 radiotherapy fractions with or without concurrent chemotherapy excluding those intolerant to xanthines, with any bleeding tendency were included. Sixty patients were enrolled; 30 patients received radiotherapy (control group) and 30 patients received radiotherapy with pentoxifylline and vitamin E (intervention group). The incidence, severity, onset and duration of oral mucositis and/or dysphagia were assessed. Locoregional control, quality of life, need for hospitalization, radiotherapy breaks, and adverse events were recorded and compared between groups. Pentoxifylline and vitamin E combination did not affect the incidence or the onset of oral mucositis or dysphagia. After adjusting for age, the combination reduced the incidence of severe oral mucositis (p = 0.01) and dysphagia (p = 0.012). The combination decreased the duration of oral mucositis and dysphagia by 5 weeks (p = 0.002) and 4 weeks (p = 0.003), respectively. The study drugs reduced the need for hospitalization (p = 0.002) and for radiotherapy breaks (p = 0.002) with improvement of FOIS (p = 0.014), EQ-5D index (p = 0.009) and VAS score (p = 0.012). Pentoxifylline and vitamin E decreased the occurrence of dysgeusia (p = 0.026) and fatigue (p = 0.026) without compromising locoregional control. Pentoxifylline/vitamin E combination reduced the severity and duration of acute radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients.
Trial registry ClinicalTrials.gov registration number: NCT02397486.
Similar content being viewed by others
References
Walden MJ, Aygun N. Head and neck cancer. Semin Roentgenol. 2013;48(1):75–86. https://doi.org/10.1053/j.ro.2012.09.002.
Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–48. https://doi.org/10.1001/jamaoncol.2016.5688.
Mendenhall WM, Dagan R, Bryant CM, Fernandes R. Radiation oncology for head and neck cancer: current standards and future changes. Oral Maxillofac Surg Clin N Am. 2018. https://doi.org/10.1016/j.coms.2018.08.003.
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015;33(2):156–64. https://doi.org/10.1200/jco.2014.56.5218.
Andreassen CN, Eriksen JG, Jensen K, Hansen CR, Sørensen BS, Lassen P, et al. IMRT—biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncol. 2018;86:91–9. https://doi.org/10.1016/j.oraloncology.2018.09.001.
Pareek P, Samdariya S, Sharma A, Gupta N, Shekhar S, Kirubakaran R. Pentoxifylline and vitamin E alone or in combination for preventing and treating side effects of radiation therapy and concomitant chemoradiotherapy. Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858.cd012117.
Patyar RR, Patyar S. Role of drugs in the prevention and amelioration of radiation induced toxic effects. Eur J Pharmacol. 2018;819:207–16. https://doi.org/10.1016/j.ejphar.2017.12.011.
Misirlioglu CH, Demirkasimoglu T, Kucukplakci B, Sanri E, Altundag K. Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer. Med Oncol. 2007;24(3):308–11. https://doi.org/10.1007/s12032-007-0006-z.
Lyons AJ, Brennan PA. Pentoxifylline—a review of its use in osteoradionecrosis. Br J Oral Maxillofac Surg. 2017;55(3):230–4. https://doi.org/10.1016/j.bjoms.2016.12.006.
Crary MA, Mann GDC, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005;86(8):1516–20. https://doi.org/10.1016/j.apmr.2004.11.049.
EuroQolGroup. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands). 1990;16(3):199–208.
Jelsma J, Hansen K, de Weerdt W, de Cock P, Kind P. How do Zimbabweans value health states? Popul Health Metrics. 2003;1(1):11. https://doi.org/10.1186/1478-7954-1-11.
Nishimura N, Nakano K, Ueda K, Kodaira M, Yamada S, Mishima Y, et al. Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer. 2012;20(9):2053–9. https://doi.org/10.1007/s00520-011-1314-6.
Le QT, Kim HE, Schneider CJ, Murakozy G, Skladowski K, Reinisch S, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011;29(20):2808–14. https://doi.org/10.1200/jco.2010.32.4095.
Moss RW. Do antioxidants interfere with radiation therapy for cancer? Integr Cancer Ther. 2007;6(3):281–92. https://doi.org/10.1177/1534735407305655.
Nieder C, Zimmermann FB, Adam M, Molls M. The role of pentoxifylline as a modifier of radiation therapy. Cancer Treat Rev. 2005;31(6):448–55. https://doi.org/10.1016/j.ctrv.2005.07.007.
Bhatt AD, Goodwin N, Cash E, Bhatt G, Silverman CL, Spanos WJ, et al. Impact of transcutaneous neuromuscular electrical stimulation on dysphagia in patients with head and neck cancer treated with definitive chemoradiation. Head Neck. 2014;37(7):1051–6. https://doi.org/10.1002/hed.23708.
Sroussi HY, Jessri M, Epstein J. Oral assessment and management of the patient with head and neck cancer. Oral Maxillofacl Surg Clin North Am. 2018;30(4):445–58. https://doi.org/10.1016/j.coms.2018.06.006.
Carmignani I, Locatello LG, Desideri I, Bonomo P, Olmetto E, Livi L, et al. Analysis of dysphagia in advanced-stage head-and-neck cancer patients: impact on quality of life and development of a preventive swallowing treatment. Eur Arch Oto-Rhino-Laryngol. 2018;275(8):2159–67. https://doi.org/10.1007/s00405-018-5054-9.
Duncan W, MacDougall RH, Kerr GR, Downing D. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer. Radiother Oncol. 1996;41(3):203–7. https://doi.org/10.1016/s0167-8140(96)01838-5.
Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008;13(8):886–98. https://doi.org/10.1634/theoncologist.2008-0024.
Murtaza B, Hichami A, Khan AS, Ghiringhelli F, Khan NA. Alteration in taste perception in cancer: causes and strategies of treatment. Front Physiol. 2017. https://doi.org/10.3389/fphys.2017.00134.
Funding
No pharmaceutical or industrial support. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Data acquisition and analysis were performed by RS. The first draft of the manuscript was written by RS and LEWl. All authors revised and commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Research Ethics Committee-Ain Shams University) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sayed, R., El Wakeel, L., Saad, A.S. et al. Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study. Med Oncol 37, 8 (2020). https://doi.org/10.1007/s12032-019-1334-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-019-1334-5